{"task_id": "e7bc740bfc7034b5", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 187/464)", "text": "o bone marrow/blood/CNS\nNon-Hodgkin\u2019s Lymphoma\n175\n\n--- Page 197 ---\nMANAGEMENT (CONT\u2019D)\ndisease and normal LDH), give CODOX MR (cyclo\nphosphamide, doxorubicin, vincristine, metho\ntrexate, rituximab) \u00031 then restage. If CR/PR,\ngive IVAC R (ifosfamide, etoposide, cytarabine)\n\u00031 then CODOX MR \u00031; otherwise, give IVAC R\n\u00031 then proceed to stem cell transplant. For high\nrisk disease, give CODOX MR \u00031, IVAC R \u00031 then\nrestage. If CR/PR and no marrow infiltration at\ndiagnosis, then autologous stem cell transplant;\notherwise, individualized higher intensity treat\nment. Allogeneic transplant may be considered\n(balance between time to find allogeneic donor\nand use of contaminated stem cells). A total of 8\ndoses of intrathecal chemotherapy should be\ngiven during treatment course. All patients should\nreceive tumor lysis syndrome prophylaxis (hydra\ntion, allopurinol). Cure rate \u000560%\n\u0002\nACUTE\nLYMPHOBLASTIC\nLYMPHOMA\nexpedited\nstaging (within 1 2 days). For most patients,\nallogeneic/autologous\nstem\ncell\ntransplant\nplus intrathecal chemotherapy (allogeneic if\nleukemic,\notherwise,\nautologous).\nAnother\noption is the hyper CVAD/methotrexate/cytara\nbine regimen. All patients should receive tumor\nlysis\nsyndrome\nprophylaxis\n(hydration,\nallopurinol)\nTREATMENT ISSUES\nINTERNATIONAL WORKSHOP CRITERIA FOR\nTREATMENT RESPONSE FOR HODGKIN\u2019S AND\nNON HODGKIN\u2019S LYMPHOMA\nCOMPLETE REMISSION (CR)\ndisappearance of\nall evidence of disease\n\u0002 Nodal masses: if FDG avid or PET positive prior\nto therapy, mass of any size permitted if PET\nnegative. If variably FDG avid or PET negative,\nregression to normal size on CT required\n\u0002 Liver\nand\nspleen:\nnot\npalpable,\nnodules\ndisappeared\n\u0002 Bone marrow: infiltrate cleared on repeat\nbiopsy; if indeterminate by morphology, immu\nnohistochemistry should be negative\nPARTIAL REMISSION (PR)\nregression of measur\nable disease and no new sites\n\u0002 Nodal masses: \u000650% decrease in sum of the\nproduct of the diameter (SPD) of up to 6 largest\ndominant masses; no increase in size of other\nnodes. If FDG avid or PET positive prior to ther\napy, one or more PET positive at previously\ninvolved site; or if variably FDG avid or PET\nnegative, regression on CT \u000650% decrease in\nSPD of nodules (for single nodule in greatest\ntransverse diameter)\n\u0002 Liver and spleen: no increase in size\nTREATMENT ISSUES (CONT\u2019D)\n\u0002 Bone marrow: irrelevant if positive prior to\ntherapy; cell type should be specified\nSTABLE DISEASE (SD)\nfailure to attain CR/PR or PD\n\u0002 Nodal masses: if FDG avid or PET positive prior\nto therapy, PET positive at prior sites of disease\nand no new sites on CT or PET. If variably FDG\navid or PET negative, no change in size of pre\nvious lesions on CT\nRELAPSED DISEASE (RD) OR PROGRESSIVE DIS\nEASE (PD)\nany new lesion or increase by \u000650%\nof previously involved sites from nadir\n\u0002 Nodal masses: appearance of a new lesion(s)\n>1.5 cm in any axis, \u000650% increase in SPD of more\nthan one node, or \u000650% increase in longest dia\nmeterof apreviouslyidentifiednode>1 cm in short\naxis. Lesions PET positive if FDG avid lymphoma or\nPET positive prior to therapy\n\u0002 Liver and spleen: >50% increase from nadir in\nthe SPD of any previous lesions\n\u0002 Bone marrow: new or recurrent involvement\nJCO 2007 25:5\nSPECIFIC ENTITIES\nEYE LYMPHOMA\n\u0002\nPATHOPHYSIOLOGY\nperiorbital involvement (mostly\nMALT type) or intraocular involvement (usually\nDLBCL with more indolent course)\n\u0002\nTREATMENTS\nfor periorbital MALT, involved field\nradiation if localized disease or CVP if widespread\ndisease. For intraocular disease, steroids, and\ninvolved field radiation. High dose methotrexate\nmay be useful\nPRIMARY CNS LYMPHOMA\n\u0002\nPATHOPHYSIOLOGY\nusually multifocal but con\nfined to CNS. May have leptomeningeal or intrao\ncular involvement. Frequently aggressive B cell\nlymphoma\n\u0002\nCLINICAL FEATURES\nfocal neurological deficit, per\nsonality\nchange,\nmild\ndementia,\npersistent\nheadache\n\u0002\nDIAGNOSIS\nCT or MRI head, lumbar puncture, slit\nlamp examination. If CNS lymphoma in the differ\nential, try to avoid giving steroids before biopsy\n\u0002\nTREATMENTS\nhigh dose corticosteroid with high\ndose methotrexate is preferred. Whole brain radia\ntion represents an alternative. Prognosis is 60% 2\nyear survival and 30% 5 year survival\nLEPTOMENINGEAL MENINGITIS\n\u0002\nRISK FACTORS\naggressive lymphomas (lympho\nblastic lymphoma, DLBCL, Burkitt\u2019s lymphoma,\nMCL), extranodal sites involvement (bone marrow,\ntesticular, paranasal, retroperitoneal lymph nodes),\nany of the five IPI prognostic factors\n176\nNon-Hodgkin\u2019s Lymphoma", "text_length": 4470, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 187/464)", "type": "chunk", "chunk_index": 186, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.502952", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.503707", "status": "complete", "chunks_added": 3}